Accordingly, we demonstrated previously that the blockage of ILT3 during the priming of T cells by tolerogenic DCs can also block the suppressive properties of IL-10-producing CD4 and CD8 T cells 19, which could be harnessed for the development of tumour therapy. This evidence concerns the gene CD8A and neoplasm.